aprosulate

01/01/1991 - "5. In subchronic toxicologic studies in rats, LW 10082 was well tolerated up to a dosage of 100 mg/kg body weight. "
10/15/1993 - "Twelve healthy male volunteers received subcutaneous injections of placebo on the first day followed by ascending doses of aprosulate in the range of 0.25 mg/kg to 2.0 mg/kg body weight on alternate days. "
07/01/1999 - "Eighteen healthy volunteers aged 21 to 30 years received two single subcutaneous doses of aprosulate (0.5 mg/kg body weight; 1.0 mg/kg body weight), or unfractionated heparin (Calciparin 7,500 IU). "

07/01/1999 - "Further clinical trials will have to establish whether aprosulate is an effective drug for the prophylaxis of deep venous thrombosis."

01/01/1996 - "Aprosulate (1-30 mg/kg, i.v.) inhibited thrombus formation in a dose-dependent manner. "
05/01/1996 - "Our results suggest that combinations of LW 10082 with LMWH may provide a new approach to more effective prophylaxis and treatment of venous or arterial thrombosis."
05/01/1996 - "The minimal effective dose of LW 10082 which significantly inhibited thrombus formation was 5 mg/kg. The antithrombotic effect of Aspisol has been investigated after its oral application at doses of 1.5 and 10 mg/kg 2 h before studying the antithrombotic effect. "
05/01/1996 - "Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model."
05/01/1996 - "We investigated the comparative antithrombotic properties of LW 10082, acetylasalicylic acid (Aspisol), low molecular weight heparin (LMWH, CY 216) and sodium heparin using laser-induced thrombosis model. "